Your browser doesn't support javascript.
loading
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index.
Legge, Alexandra; Kirkland, Susan; Rockwood, Kenneth; Andreou, Pantelis; Bae, Sang-Cheol; Gordon, Caroline; Romero-Diaz, Juanita; Sanchez-Guerrero, Jorge; Wallace, Daniel J; Bernatsky, Sasha; Clarke, Ann E; Merrill, Joan T; Ginzler, Ellen M; Fortin, Paul R; Gladman, Dafna D; Urowitz, Murray B; Bruce, Ian N; Isenberg, David A; Rahman, Anisur; Alarcón, Graciela S; Petri, Michelle; Khamashta, Munther A; Dooley, M A; Ramsey-Goldman, Rosalind; Manzi, Susan; Zoma, Asad A; Aranow, Cynthia; Mackay, Meggan; Ruiz-Irastorza, Guillermo; Lim, S Sam; Inanc, Murat; van Vollenhoven, Ronald F; Jonsen, Andreas; Nived, Ola; Ramos-Casals, Manuel; Kamen, Diane L; Kalunian, Kenneth C; Jacobsen, Soren; Peschken, Christine A; Askanase, Anca; Hanly, John G.
Afiliación
  • Legge A; Dalhousie University, Halifax, Nova Scotia, Canada.
  • Kirkland S; Dalhousie University, Halifax, Nova Scotia, Canada.
  • Rockwood K; Dalhousie University, Halifax, Nova Scotia, Canada.
  • Andreou P; Dalhousie University, Halifax, Nova Scotia, Canada.
  • Bae SC; Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
  • Gordon C; University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.
  • Romero-Diaz J; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico.
  • Sanchez-Guerrero J; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico.
  • Wallace DJ; Cedars-Sinai Medical Center and David Geffen School of Medicine at University of California, Los Angeles.
  • Bernatsky S; McGill University, Montreal, Quebec, Canada.
  • Clarke AE; University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
  • Merrill JT; Oklahoma Medical Research Foundation, Oklahoma City.
  • Ginzler EM; SUNY Downstate Medical Center, New York, New York.
  • Fortin PR; CHU de Quebec-Université Laval, Quebec City, Quebec, Canada.
  • Gladman DD; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Urowitz MB; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Bruce IN; Arthritis Research UK Epidemiology Unit, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Centre, and Manchester University NHS Foundation Trust, Manchester, UK.
  • Isenberg DA; University College London, London, UK.
  • Rahman A; University College London, London, UK.
  • Alarcón GS; University of Alabama at Birmingham.
  • Petri M; Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Khamashta MA; St. Thomas Hospital and King's College London GKT School of Medical Education, London, UK.
  • Dooley MA; University of North Carolina at Chapel Hill.
  • Ramsey-Goldman R; Northwestern University and Feinberg School of Medicine, Chicago, Illinois.
  • Manzi S; Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, Pennsylvania.
  • Zoma AA; Hairmyres Hospital, East Kilbride, UK.
  • Aranow C; Feinstein Institute for Medical Research, Manhasset, New York.
  • Mackay M; Feinstein Institute for Medical Research, Manhasset, New York.
  • Ruiz-Irastorza G; Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain.
  • Lim SS; Emory University School of Medicine, Atlanta, Georgia.
  • Inanc M; Istanbul University, Istanbul, Turkey.
  • van Vollenhoven RF; Karolinska Institute, Stockholm, Sweden.
  • Jonsen A; Lund University, Lund, Sweden.
  • Nived O; Lund University, Lund, Sweden.
  • Ramos-Casals M; Institut d'Investigacions Biomèdiques August Pi i Sunyer and Hospital Clínic, Barcelona, Barcelona, Spain.
  • Kamen DL; Medical University of South Carolina, Charleston.
  • Kalunian KC; University of California, San Diego School of Medicine.
  • Jacobsen S; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Peschken CA; University of Manitoba, Winnipeg, Manitoba, Canada.
  • Askanase A; Hospital for Joint Diseases, New York University New York, New York.
  • Hanly JG; Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.
Arthritis Rheumatol ; 72(4): 658-666, 2020 04.
Article en En | MEDLINE | ID: mdl-31631584
OBJECTIVE: The Systemic Lupus International Collaborating Clinics (SLICC) frailty index (FI) has been shown to predict mortality, but its association with other important outcomes is unknown. We examined the association of baseline SLICC FI values with damage accrual in the SLICC inception cohort. METHODS: The baseline visit was defined as the first visit at which both organ damage (SLICC/American College of Rheumatology Damage Index [SDI]) and health-related quality of life (Short Form 36) were assessed. Baseline SLICC FI scores were calculated. Damage accrual was measured by the increase in SDI between the baseline assessment and the last study visit. Multivariable negative binomial regression was used to estimate the association between baseline SLICC FI values and the rate of increase in the SDI during follow-up, adjusting for relevant demographic and clinical characteristics. RESULTS: The 1,549 systemic lupus erythematosus (SLE) patients eligible for this analysis were mostly female (88.7%) with a mean ± SD age of 35.7 ± 13.3 years and a median disease duration of 1.2 years (interquartile range 0.9-1.5 years) at baseline. The mean ± SD baseline SLICC FI was 0.17 ± 0.08. Over a mean ± SD follow-up of 7.2 ± 3.7 years, 653 patients (42.2%) had an increase in SDI. Higher baseline SLICC FI values (per 0.05 increase) were associated with higher rates of increase in the SDI during follow-up (incidence rate ratio [IRR] 1.19 [95% confidence interval 1.13-1.25]), after adjusting for age, sex, ethnicity/region, education, baseline SLE Disease Activity Index 2000, baseline SDI, and baseline use of glucocorticoids, antimalarials, and immunosuppressive agents. CONCLUSION: Our findings indicate that the SLICC FI predicts damage accrual in incident SLE, which further supports the SLICC FI as a valid health measure in SLE.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Fragilidad / Lupus Eritematoso Sistémico Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Rheumatol Año: 2020 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Fragilidad / Lupus Eritematoso Sistémico Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Rheumatol Año: 2020 Tipo del documento: Article País de afiliación: Canadá